Cancer Tumor Profiling Market

The cancer tumor profiling market is projected to reach USD 19.87 billion by 2031 from USD 12.02 billion in 2026, at a CAGR of 10.6%.

The cancer tumor profiling market is projected to grow strongly, supported by the increasing adoption of precision oncology, the broader use of next-generation sequencing (NGS), PCR, immunohistochemistry (IHC), and in situ hybridization (ISH), and the expanding role of biomarker-driven treatment selection. Growth is also being supported by the rising use of tissue- and blood-based profiling, increasing pharmaceutical-companion diagnostic co-development, and the wider application of tumor profiling for treatment response, resistance monitoring, minimal residual disease assessment, surveillance, and recurrence detection.

To know about the assumptions considered for the study download the pdf brochure

The global cancer tumor profiling market is moderately fragmented, with leading players such as F. Hoffmann-La Roche AG (Switzerland), Illumina, Inc. (US), Guardant Health, Inc (US), Tempus AI, Inc. (US), Thermo Fisher Scientific Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), NeoGenomics, Inc. (US), Myriad Genetics, Inc. (US), Agilent Technologies, Inc. (US), Quest Diagnostics Incorporated (US), Caris Life Sciences, Inc. (US), Danaher Corporation (US), QIAGEN (Netherlands), and Abbott (US). These companies are strengthening their market positions through regulatory approvals, portfolio expansion, pharmaceutical partnerships, liquid biopsy innovation, integrated clinical and molecular data capabilities, and geographic expansion.

F. Hoffmann-La Roche AG

F. Hoffmann-La Roche AG is the leading participant in the cancer tumor profiling market, supported by its integrated pharmaceuticals and diagnostics model and its broad presence across tissue pathology, molecular diagnostics, comprehensive genomic profiling, and companion diagnostics. Through Foundation Medicine, Roche offers tissue-, blood-, and hematologic malignancy-focused profiling solutions, including FoundationOne CDx, FoundationOne Liquid CDx, and FoundationOne Heme. Roche also participates in tissue-based oncology testing through its VENTANA portfolio. The combination of pharmaceutical development, diagnostic assay capabilities, regulatory expertise, and biomarker-driven therapy partnerships strengthens Roche's position across both clinical testing and biopharmaceutical service applications.

Illumina, Inc.

Illumina, Inc. is a major participant in the cancer tumor profiling market through its global sequencing platform, installed base, sequencing consumables, and distributed oncology assay portfolio. TruSight Oncology Comprehensive and the TruSight Oncology 500 family support comprehensive genomic profiling and multi-biomarker assessment across solid tumors. Illumina's sequencing ecosystem, bioinformatics capabilities, and companion diagnostic collaborations with pharmaceutical companies strengthen its role in clinical oncology testing, translational research, and therapy-linked biomarker development.

Guardant Health, Inc.

Guardant Health, Inc. is a leading precision oncology company with a strong position in blood-based tumor profiling. Its portfolio includes Guardant360 CDx for advanced-cancer genomic profiling, Guardant Reveal for residual disease and recurrence surveillance, and GuardantINFINITY for biopharmaceutical research and data applications. The company's specialization in circulating tumor DNA, clinical evidence generation, and pharmaceutical partnerships supports its competitive position in treatment selection, monitoring, clinical-trial development, and biomarker-driven drug programs.

Tempus AI, Inc.

Tempus AI, Inc. is a prominent precision medicine company combining molecular diagnostics, clinical data, and AI-enabled analytical capabilities. Its tumor profiling portfolio includes xT and xT CDx for tissue-based testing and xF and xF+ for blood-based profiling. Tempus also supports biopharmaceutical customers through data, biomarker, and clinical-trial services. Its integration of diagnostic testing with longitudinal clinical and molecular data differentiates the company in treatment selection, patient stratification, clinical-trial enrolment, and drug-development applications.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. has broad capabilities across NGS, PCR, digital PCR, reagents, instruments, companion diagnostic development, and clinical research services. Its Ion Torrent and Oncomine portfolios support targeted and comprehensive profiling across solid tumors and hematologic malignancies. The FDA-approved Oncomine Dx Express Test, used with the Ion Torrent Genexus Dx Integrated Sequencer, supports rapid tumor profiling and companion diagnostic applications. Thermo Fisher's end-to-end workflow, automation, assay-development expertise, and biopharmaceutical relationships support its position across both product and service segments of the market.

Market Ranking

The cancer tumor profiling market is characterized by moderate fragmentation. The top five companies collectively accounted for approximately 35–39% of total global market revenue in 2025, led by F. Hoffmann-La Roche AG, Guardant Health, Inc., Illumina, Inc., Tempus AI, Inc., and Thermo Fisher Scientific Inc. The market is distributed among diversified diagnostics companies, specialty molecular laboratories, genomic profiling service providers, tissue-pathology companies, regional reference laboratories, CROs, and emerging precision-oncology participants. Competition is therefore capability-led across instruments, assays, testing services, clinical data, and biopharmaceuticals.

F. Hoffmann-La Roche AG (Switzerland) maintains a leading position through its integrated diagnostics and pharmaceutical ecosystem, broad oncology biomarker portfolio, and capabilities spanning IHC, ISH, PCR, NGS, tissue profiling, liquid biopsy, and comprehensive genomic profiling.

Guardant Health, Inc. (US) is a leading specialist in liquid biopsy and blood-based precision oncology, with offerings supporting advanced cancer profiling, residual disease monitoring, and biopharmaceutical research. Illumina, Inc. (US) supports the market through sequencing instruments, consumables, oncology assays, informatics, and companion diagnostic partnerships. Tempus AI, Inc. (US) differentiates itself through the integration of molecular testing with clinical data, AI-enabled analytics, and clinical-trial services. Thermo Fisher Scientific Inc. (US) provides NGS and PCR-based workflows, Oncomine assays, automated sequencing platforms, and companion diagnostic development capabilities.

Agilent Technologies, Inc. (US) competes through Dako-branded IHC and ISH solutions, companion diagnostics, and cancer genomics workflows. QIAGEN N.V. (Netherlands) provides therascreen PCR assays, QIAseq panels, sample-preparation technologies, and bioinformatics across the sample-to-insight workflow. Danaher Corporation (US), through businesses such as Leica Biosystems, Cepheid, and Beckman Coulter, participates in tissue pathology, molecular testing, and laboratory workflows. Caris Life Sciences, Inc., NeoGenomics, Inc., Laboratory Corporation of America Holdings, and Quest Diagnostics Incorporated also compete through comprehensive genomic profiling, specialty oncology testing, pathology, reference-laboratory scale, and biopharmaceutical services.

The remainder of the market is fragmented across regional diagnostic developers, specialist molecular diagnostics companies, hospital & academic medical-center laboratories, CROs and central laboratories, and emerging precision-oncology firms. These participants compete through niche biomarker expertise, local reimbursement and regulatory access, specialized tissue or liquid biopsy capabilities, customized assay development, rapid turnaround times, and collaborations with pharmaceutical and biotechnology companies for targeted therapy-linked diagnostic development.

Related Reports:

Cancer Tumor Profiling Market by Product & Service Offering (Instruments/Systems, Assays/Kits, Services), Technology (NGS, PCR, IHC, ISH/FISH), Sample Type (Tissue, Blood, Bone Marrow), Application, Cancer Type, End User & Region – Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]